Scale-up and post-approval changes MCQs With Answer

Scale-up and post-approval changes MCQs With Answer (Regulatory Affairs, MPH 104T)

Scaling up a formulation and managing post-approval changes (SUPAC) are pivotal capabilities for M. Pharm students specializing in Regulatory Affairs. This MCQ set simplifies the complex regulatory expectations surrounding process and site changes, equipment and batch-size modifications, excipient and composition changes, and dossier filing strategies across US FDA and EU pathways. You will test your understanding of key guidances such as FDA SUPAC-IR/MR/SS, ICH Q8–Q12, and critical concepts like control strategy, dissolution similarity (f2), BCS-based biowaivers, IVRT, and PACMP. Each question is designed to connect science with regulation—linking CQAs/CPPs, risk management, and validation—to prepare you for real-world submission planning and compliant lifecycle management.

Q1. What is the primary purpose of FDA’s SUPAC guidance for oral dosage forms?

• To replace process validation with real-time release testing
• To provide recommendations for CMC documentation, dissolution, and bioequivalence after post-approval changes
• To harmonize global GMP requirements under ICH
• To eliminate the need for agency review for minor changes

Correct Answer: To provide recommendations for CMC documentation, dissolution, and bioequivalence after post-approval changes

Q2. Which US FDA submission category requires agency approval before distribution of product made with the change?

• Annual Report (AR)
• Changes Being Effected in 0 days (CBE-0)
• Changes Being Effected in 30 days (CBE-30)
• Prior Approval Supplement (PAS)

Correct Answer: Prior Approval Supplement (PAS)

Q3. In dissolution profile comparison, which metric and range typically support similarity between pre- and post-change products?

• f1 between 0 and 15
• f2 between 50 and 100
• AUC ratio between 0.75 and 1.25
• RSD less than 2%

Correct Answer: f2 between 50 and 100

Q4. According to ICH Q12, what tool enables a pre-agreed plan with regulators to manage specific post-approval changes?

• Control strategy
• Bracketing and matrixing
• Post-Approval Change Management Protocol (PACMP)
• Product lifecycle management (PLCM) report only

Correct Answer: Post-Approval Change Management Protocol (PACMP)

Q5. For a modified-release (MR) tablet, which change is generally considered “major” and likely to require a PAS with in vivo BE?

• Increase in batch size using the same equipment and operating parameters
• Change in colorant concentration within established limits
• Change in release-controlling polymer type
• Adding a non-functional film coat of the same composition

Correct Answer: Change in release-controlling polymer type

Q6. Which statement best reflects conditions supporting a BCS Class I biowaiver for post-approval changes?

• Drug is highly soluble, low permeability; rapid dissolution only at pH 1.2
• Drug is highly soluble, highly permeable; rapid dissolution in multiple media and excipients do not affect absorption
• Drug is low solubility, highly permeable; very rapid dissolution in water
• Any drug can qualify if f2 ≥ 50 in one medium

Correct Answer: Drug is highly soluble, highly permeable; rapid dissolution in multiple media and excipients do not affect absorption

Q7. Under SUPAC concepts, changing from a high-shear granulator to a fluid-bed granulator generally represents which type of equipment change?

• Same design and operating principle
• Different design but same operating principle
• Different operating principle
• No change category; always minor

Correct Answer: Different operating principle

Q8. During mixing scale-up of a shear-sensitive suspension, which parameter is commonly targeted to preserve similar shear environment across scales?

• Constant residence time
• Constant power per unit volume
• Constant batch mass
• Constant Reynolds number is never applied in pharma

Correct Answer: Constant power per unit volume

Q9. In the EU Variations system, which category corresponds to “do-and-tell” minor changes with immediate implementation and notification within a defined period?

• Type IA
• Type IB
• Type II
• Extension

Correct Answer: Type IA

Q10. In vitro release testing (IVRT) is especially relevant for assessing post-approval changes in which dosage forms?

• Immediate-release tablets
• Sterile parenterals only
• Semisolid dermatologicals (creams, ointments, gels)
• Hard gelatin capsules only

Correct Answer: Semisolid dermatologicals (creams, ointments, gels)

Q11. Which validation/testing strategy is often used to optimize stability studies when scaling up with multiple strengths or container sizes?

• Concurrent validation only
• Parametric release
• Bracketing and matrixing
• Skip-lot testing

Correct Answer: Bracketing and matrixing

Q12. Which statement best aligns with ICH Q10 change management in the context of SUPAC?

• Changes should be implemented first, then risk assessed
• Risk-based change control links CPPs to CQAs and defines verification/validation needs
• Only QA approves changes; cross-functional science input is discouraged
• Design space eliminates the need for change control

Correct Answer: Risk-based change control links CPPs to CQAs and defines verification/validation needs

Q13. What is a key regulatory benefit of an approved comparability protocol/PACMP?

• It removes all testing requirements for future changes
• It can enable a lower reporting category for pre-defined changes if criteria are met
• It allows unlimited equipment changes without notification
• It replaces bioequivalence studies in every case

Correct Answer: It can enable a lower reporting category for pre-defined changes if criteria are met

Q14. For a non-sterile immediate-release tablet, moving manufacturing to a different building with the same equipment, process, and controls typically aligns with which US FDA reporting pathway (absent other risks)?

• Annual Report (AR)
• Changes Being Effected in 30 days (CBE-30)
• Changes Being Effected in 0 days (CBE-0)
• No reporting required

Correct Answer: Changes Being Effected in 30 days (CBE-30)

Q15. For dissolution profile similarity assessment using f2, what is the minimum number of units per lot typically recommended?

• 6 units
• 10 units
• 12 units
• 24 units

Correct Answer: 12 units

Q16. In which scenario is an in vivo bioequivalence study commonly waived for an IR product after a moderate post-approval change?

• When the API crystal form is changed
• When dissolution similarity (f2) is shown across multiple media and excipients remain within SUPAC-recommended ranges
• When packaging artwork is updated
• When equipment is replaced with a different operating principle

Correct Answer: When dissolution similarity (f2) is shown across multiple media and excipients remain within SUPAC-recommended ranges

Q17. Which change in an MR product is most likely to trigger a PAS due to potential impact on release kinetics?

• Switching to a bottle cap with the same liner material
• Changing from a hydrophilic matrix to a membrane-coated reservoir system
• Reducing overage of a non-functional excipient within range
• Adding a flavor within IIG limits

Correct Answer: Changing from a hydrophilic matrix to a membrane-coated reservoir system

Q18. Following a significant manufacturing change, how many consecutive commercial-scale PPQ batches are typically expected to demonstrate process performance qualification?

• 1 batch
• 2 batches
• 3 batches
• 5 batches

Correct Answer: 3 batches

Q19. For an IR tablet, changing to a different grade of a compendial excipient (same manufacturer) without functional change most commonly aligns with which reporting category?

• Prior Approval Supplement (PAS)
• Changes Being Effected in 30 days (CBE-30)
• Annual Report (AR)
• No reporting required globally

Correct Answer: Annual Report (AR)

Q20. Which risk management approach from ICH Q9 is most appropriate to justify testing scope and filing strategy during scale-up?

• Fishbone diagram only, without data
• Failure Mode and Effects Analysis (FMEA) linking CPPs to CQAs and control strategy
• 100% end-product testing in place of risk assessment
• Supplier audit alone

Correct Answer: Failure Mode and Effects Analysis (FMEA) linking CPPs to CQAs and control strategy

Download